Requip Tablets

Requip (ropinirole) is an oral tablet that we list in four strengths: 0.25 mg, 0.5 mg, 1 mg, and 2 mg. The practical choice is therefore not just the product name. It is the prescribed strength and a package quantity that fits the current stage of treatment. Ropinirole is commonly started at a low dose and adjusted gradually, so the strength or number of tablets needed may change during titration. Our guide explains the package options we offer, how to interpret their unit value, and which medical and practical factors to check before ordering.

Package Sizes and Unit Value

Our Requip listings cover package quantities from 30 to 360 tablets, although not every quantity is available for every strength. The comparison below shows the exact combinations we currently offer, together with our current prices, per-tablet values, and relative savings. It is the appropriate place to compare the figures because prices and availability can change; we do not reproduce every row in the surrounding text.

A lower per-tablet price can make a larger package look attractive, but unit value is only one part of the decision. A package is not good value if the dose changes before all the tablets can be used or if the tablets pass their expiry date. Conversely, someone taking a stable prescribed dose may find that an appropriate larger quantity reduces the frequency of reordering. The price comparison should therefore be read alongside the prescribed dose, anticipated review dates, and the expiry information on the supplied container.

The price comparison image covers only the options and prices available from us. It does not represent a Canadian market average, a local pharmacy price, an insurance copayment, or a public drug-plan reimbursement amount. Those figures are not interchangeable with our catalogue prices.

Which Strength and Quantity Fit the Prescribed Plan?

The four strengths are separate oral tablet products, not interchangeable quantities of the same tablet. The selected strength should match the prescription or the directions supplied by the prescriber. Taking extra lower-strength tablets or splitting a tablet to reproduce another strength should not be assumed to be appropriate unless a prescriber or pharmacist has specifically confirmed it for the product supplied.

Ropinirole dosing differs between Parkinson's disease and restless legs syndrome, and dose increases are normally made in stages. These points can help frame a package decision without replacing individualized medical advice:

• Check the exact strength. Confirm that the strength shown in our listing matches the current directions. Requip 0.25 mg, 0.5 mg, 1 mg, and 2 mg tablets are distinct options.
• Consider the stage of titration. If the dose is being adjusted, a smaller available quantity may limit unused tablets if the strength changes at the next review.
• Review the expected duration. If the dose has been stable and is expected to continue, compare the available quantities with the period covered by the prescribed plan rather than choosing by unit price alone.
• Account for combinations carefully. Some regimens use more than one tablet or strength. The quantity for each strength should reflect its actual place in the directions, not simply the total number of tablets taken each day.
• Check the expiry date after delivery. Do not plan to retain tablets beyond the expiry shown on their packaging.

Treatment duration, titration, and dose selection belong with the prescriber. We provide the corresponding strength and package choices in our catalogue and show their current value so that the prescribed option is easier to identify.

Brand, Generic, and Alternative Medicines

Requip is a brand name for ropinirole, a dopamine agonist. A generic ropinirole tablet contains the same active ingredient at its stated strength, but branding, appearance, inactive ingredients, manufacturer, and available package options may differ. Generic status does not make a product interchangeable with a different strength or dosage form. Anyone changing between products should confirm the active ingredient, strength, tablet directions, and product information with a pharmacist or prescriber.

Ropinirole is also not a direct substitute for another medicine used in Parkinson's disease or restless legs syndrome. Depending on the condition and clinical circumstances, a prescriber may consider medicines such as pramipexole, rotigotine, levodopa/carbidopa, rasagiline, selegiline, Amantadine, apomorphine, or gabapentin enacarbil. These medicines differ in mechanism, dosage form, dosing schedule, indications, and adverse-effect profile. Switching to or combining one of them with ropinirole requires a clinical decision rather than a price-based product substitution.

Established Uses of Requip

Oral ropinirole tablets are authorized in Canada for adults with idiopathic Parkinson's disease and for adults with moderate-to-severe primary restless legs syndrome. In Parkinson's disease, ropinirole may help manage movement-related symptoms associated with reduced dopamine activity. In restless legs syndrome, it can reduce the uncomfortable urge to move the legs, particularly when symptoms occur during rest or in the evening.

Ropinirole belongs to the dopamine agonist class. It acts at dopamine receptors rather than being converted into dopamine in the way levodopa is. This difference helps explain why ropinirole and levodopa-based treatments are distinct options and may have different dosing and adverse-effect considerations.

The same tablet strengths may appear in treatment plans for either approved condition, but the schedules are not the same. The diagnosis, timing of doses, titration plan, and treatment goals should come from the prescriber. The availability of a particular strength or larger package from us does not determine which regimen is medically appropriate.

How Ropinirole Is Taken and Stored

Requip tablets are swallowed by mouth according to the prescribed schedule. They may generally be taken with or without food; taking a dose with food may help if nausea occurs. Because schedules differ by indication, customers should follow the directions supplied for their own treatment rather than applying instructions intended for another condition. Taking doses at consistent times can help maintain the prescribed routine.

Ropinirole is usually titrated gradually. A missed dose, an interruption lasting more than a brief period, or a decision to restart treatment may require advice because returning immediately to a previous dose may not be suitable. Ropinirole should not be stopped suddenly without medical guidance. Abrupt withdrawal can worsen symptoms and has been associated with withdrawal effects and serious reactions resembling neuroleptic malignant syndrome, including fever, marked muscle stiffness, altered consciousness, and autonomic changes.

Store the tablets at 20°C to 25°C. Brief temperature excursions from 15°C to 30°C are permitted. Protect them from light and moisture, and keep them in the original, tightly closed container. Storage in a bathroom or another humid location is unsuitable. Keep all medicines out of the sight and reach of children, and ask a pharmacist how to dispose of expired or unwanted tablets rather than placing them where another person could use them.

Safety, Side Effects, and Interactions

Ropinirole can cause drowsiness and sudden sleep onset, sometimes without warning. Affected patients should not drive, cycle in traffic, operate machinery, or perform another activity in which unexpected sleep could cause harm. This risk is especially important when treatment begins, the dose increases, or another sedating substance is used. Alcohol, sleep medicines, opioid pain medicines, sedating antihistamines, and other central nervous system depressants may increase impairment.

Commonly reported effects include nausea, dizziness, fatigue, headache, and low blood pressure when standing. Fainting, hallucinations, confusion, leg swelling, or new uncontrolled movements can also occur. Dopamine agonists may cause impulse-control problems, including compulsive gambling, shopping, eating, or sexual behaviour. A patient or family member who notices unusual urges or major behavioural changes should contact the prescriber promptly.

A medication and health review should cover several important areas:

• Dopamine-blocking medicines: Antipsychotics and medicines such as metoclopramide can oppose ropinirole's dopamine effects.
• CYP1A2 interactions: Medicines that inhibit this liver enzyme, including ciprofloxacin and fluvoxamine, can increase ropinirole exposure. A prescriber may need to reassess the dose when one is started or stopped.
• Smoking changes: Tobacco smoking can increase ropinirole metabolism. Starting or stopping smoking may alter exposure and should be reported to the prescriber.
• Blood-pressure effects: Other medicines that lower blood pressure can add to dizziness or postural hypotension.
• Pregnancy and breastfeeding: Ropinirole should not be used during pregnancy unless the expected maternal benefit outweighs the potential fetal risk. It can lower prolactin and inhibit milk production, so use while breastfeeding should be avoided unless a qualified clinician determines otherwise.
• Age: Safety and effectiveness have not been established in patients younger than 18 years.

Urgent medical help is appropriate for a severe allergic reaction, loss of consciousness, a sudden severe behavioural or mental-status change, or symptoms suggesting a serious withdrawal reaction. This overview highlights major considerations but is not a complete adverse-effect or interaction list. The product monograph, prescriber, and pharmacist remain the appropriate sources for advice based on an individual's medical history.

Canadian Access and Our Ordering Policy

Ropinirole is a prescription medicine in Canada. Health Canada's Drug Product Database is the official source for checking the current authorization and marketing status of a specific Requip or ropinirole strength and Drug Identification Number. Product labelling, authorization, and safety monitoring are regulatory matters and are separate from the way we present package options and prices.

Our ordering policy does not require a prescription to be submitted at checkout. That policy does not change ropinirole's prescription status in Canada, replace a prescriber's assessment, or mean that the medicine is suitable for self-directed use. Customers should have an established treatment plan and confirm the strength and directions with their prescriber or pharmacist before ordering.

Provincial and territorial public drug plans set their own formulary and reimbursement rules. Eligibility may depend on the province or territory, indication, product listing, and applicable coverage criteria. We do not treat potential public coverage as a discount from our catalogue price, and our checkout does not determine whether a public plan will reimburse a purchase.

What Happens After a Package Is Selected?

Once the prescribed strength and a suitable package quantity have been identified, customers can select that option from our listing and continue through our checkout. Before submitting the order, review the product name, strength, tablet quantity, price, and delivery address. For a Canadian address, the street information, municipality, province or territory, and postal code should all be complete.

Our ordering steps include:

• Select the Requip strength and package quantity that match the established treatment plan.
• Review the price and order summary before proceeding.
• Enter the delivery address and choose from the payment and shipping options shown in our checkout.
• Check the confirmation details for errors before submitting the order.
• After checkout, we pack and dispatch the accepted order, and delivery follows the shipping option and destination details shown during the ordering process.

Our support team is available 24/7 by email and online chat for questions about our listings, checkout, payment, order status, shipping, or delivery. A pharmacist is also available for product-related questions. Support can explain the options we list, but it cannot independently change a prescribed dose or choose a treatment regimen. If the dose changes after an order, contact the prescriber about medical instructions and our support team about the options available for a future order.

A Balanced Value Decision

The most useful Requip comparison starts with the correct identity: oral ropinirole tablets in the prescribed strength. The next step is to choose a package quantity that reflects the current treatment stage, expected duration, and expiry date. Only then should unit value be used to compare the suitable options.

A larger package should not be selected solely because its per-tablet cost is lower. During titration, a smaller available quantity may reduce waste; during stable treatment, an appropriate larger quantity may reduce reordering. Our package-value comparison shows how our current options differ without deciding which dose or duration is right for an individual. Before completing an order, confirm the strength and quantity, review our current price, and contact our support team if clarification about our listing or ordering process is needed.